Zim Laboratories Limited — Important, 05-06-2025: General Updates

ZIM Laboratories posted 7.2% revenue growth to ₹1,719 Cr, driven by exports (+7.6%) and rising sales of New Innovative Products and Oral Thin Films. EBITDA margin expanded to 32.6% despite higher finance costs from capex and borrowings. PAT declined 15.7% to ₹132 Cr due to increased finance expenses and geopolitical challenges impacting some legacy exports. The company bolstered its presence in developed and Pharmerging markets, invested 7.7% of revenue in R&D, and spent ₹81 Cr on capex upgrading Urology and Nutraceuticals units. Strategic partnerships in MENA and Oceania are enhancing licensing income and global growth prospects.